HTG Molecular Diagnostics Inc. [HTGM] Revenue clocked in at $6.80 million, down -93.37% YTD: What’s Next?

HTG Molecular Diagnostics Inc. [NASDAQ: HTGM] traded at a high on 12/27/22, posting a 39.03 gain after which it closed the day’ session at $4.31. The company report on December 23, 2022 that HTG Molecular Diagnostics Announces Closing of a $10 Million Public Offering.

Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.


H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.

The results of the trading session contributed to over 30883957 shares changing hands. Over the past one week, the price volatility of HTG Molecular Diagnostics Inc. stands at 64.99% while the volatility over the past one month is 54.02%.

The market cap for HTGM stock reached $5.43 million, with 0.92 million shares outstanding and 0.73 million shares in the current float. Compared to the average trading volume of 476.39K shares, HTGM reached a trading volume of 30883957 in the most recent trading day, which is why market watchdogs consider the stock to be active.

What do top market gurus say about HTG Molecular Diagnostics Inc. [HTGM]?

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for HTGM shares is $18.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on HTGM stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Cantor Fitzgerald have made an estimate for HTG Molecular Diagnostics Inc. shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on May 11, 2020. The new note on the price target was released on March 26, 2020, representing the official price target for HTG Molecular Diagnostics Inc. stock. Previously, the target price had yet another raise from $4.50 to $6, while Rodman & Renshaw kept a Buy rating on HTGM stock.

The Average True Range (ATR) for HTG Molecular Diagnostics Inc. is set at 2.72, with the Price to Sales ratio for HTGM stock in the period of the last 12 months amounting to 0.80. The Price to Book ratio for the last quarter was 3.29, with the Price to Cash per share for the same quarter was set at 5.16.

How has HTGM stock performed recently?

HTG Molecular Diagnostics Inc. [HTGM] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -56.36. With this latest performance, HTGM shares dropped by -25.19% in over the last four-week period, additionally sinking by -57.24% over the last 6 months – not to mention a drop of -92.87% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for HTGM stock in for the last two-week period is set at 45.02, with the RSI for the last a single of trading hit 43.43, and the three-weeks RSI is set at 45.59 for HTG Molecular Diagnostics Inc. [HTGM]. The present Moving Average for the last 50 days of trading for this stock 6.10, while it was recorded at 5.02 for the last single week of trading, and 10.10 for the last 200 days.

HTG Molecular Diagnostics Inc. [HTGM]: Deeper insight into the fundamentals

Operating Margin for any stock indicates how profitable investing would be, and HTG Molecular Diagnostics Inc. [HTGM] shares currently have an operating margin of -205.48 and a Gross Margin at +54.02. HTG Molecular Diagnostics Inc.’s Net Margin is presently recorded at -192.49.

Return on Equity for this stock declined to -137.80, with Return on Assets sitting at -52.23.

HTG Molecular Diagnostics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.30 and a Current Ratio set at 1.60.

Insider trade positions for HTG Molecular Diagnostics Inc. [HTGM]

There are presently around $0 million, or 4.30% of HTGM stock, in the hands of institutional investors. The top three institutional holders of HTGM stocks are: RENAISSANCE TECHNOLOGIES LLC with ownership of 7,200, which is approximately -43.908% of the company’s market cap and around 10.90% of the total institutional ownership; BLACKROCK INC., holding 6,182 shares of the stock with an approximate value of $27000.0 in HTGM stocks shares; and VIRTU FINANCIAL LLC, currently with $26000.0 in HTGM stock with ownership of nearly 451.828% of the company’s market capitalization.

Positions in HTG Molecular Diagnostics Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 4 institutional holders increased their position in HTG Molecular Diagnostics Inc. [NASDAQ:HTGM] by around 5,089 shares. Additionally, 11 investors decreased positions by around 16,917 shares, while 7 investors held positions by with 16,661 shares. The mentioned changes placed institutional holdings at 38,667 shares, according to the latest SEC report filing. HTGM stock had 1 new institutional investments in for a total of 8 shares, while 4 institutional investors sold positions of 1,730 shares during the same period.


Please enter your comment!
Please enter your name here